Treatment options for HER2-positive breast cancer are currently based on the CLEOPATRA trial, which established the combination of pertuzumab, trastuzumab, and docetaxel as the standard of care for metastatic HER2-positive breast cancer (9). The gene discussed is ERBB2; the disease is breast carcinoma.